MAP — Microba Life Sciences Income Statement
0.000.00%
- AU$85.09m
- AU$72.10m
- AU$12.09m
- 24
- 28
- 79
- 42
Annual income statement for Microba Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.91 | 3.73 | 4.69 | 5.42 | 12.1 |
Cost of Revenue | |||||
Gross Profit | 1.43 | 2.06 | 2.37 | 2.68 | 5.91 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.57 | 11.3 | 16.1 | 18.4 | 32.1 |
Operating Profit | -6.66 | -7.52 | -11.5 | -13 | -20 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.66 | -7.52 | -11.5 | -12.7 | -20 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.65 | -7.52 | -11.5 | -12.7 | -19.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.65 | -7.52 | -11.5 | -12.7 | -19.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.65 | -7.52 | -11.5 | -12.7 | -19.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.025 | -0.033 | -0.06 | -0.038 | -0.049 |
Dividends per Share |